Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial. J of Skin [Internet]. 2024 Nov. 18 [cited 2026 May 19];8(6):s488. Available from: https://skin.dermsquared.com/skin/article/view/3132